C4 Therapeutics, Inc.

NasdaqGS:CCCC 주식 보고서

시가총액: US$317.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

C4 Therapeutics 관리

관리 기준 확인 2/4

C4 Therapeutics' CEO는 Andrew Hirsch, Sep2020 에 임명되었습니다 의 임기는 3.75 년입니다. 총 연간 보상은 $ 3.79M, 16.9% 로 구성됩니다. 16.9% 급여 및 83.1% 보너스(회사 주식 및 옵션 포함). 는 $ 859.81K 가치에 해당하는 회사 주식의 0.31% 직접 소유합니다. 859.81K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 6.9 년입니다.

주요 정보

Andrew Hirsch

최고 경영자

US$3.8m

총 보상

CEO 급여 비율16.9%
CEO 임기3.8yrs
CEO 소유권0.3%
경영진 평균 재임 기간3.6yrs
이사회 평균 재임 기간6.9yrs

최근 관리 업데이트

Recent updates

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12
Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29
Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24
C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03
New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14
Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10
Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

May 04

C4 Therapeutics closes $181M capital raise

Jun 21

C4 Therapeutics gets dosing underway in early-stage CFT7455 lymphoma trial

Jun 14

C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy

Jun 07

Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

Jun 02
Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

CEO 보상 분석

Andrew Hirsch 의 보수는 C4 Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$126m

Dec 31 2023US$4mUS$639k

-US$132m

Sep 30 2023n/an/a

-US$135m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$131m

Dec 31 2022US$3mUS$614k

-US$128m

Sep 30 2022n/an/a

-US$107m

Jun 30 2022n/an/a

-US$99m

Mar 31 2022n/an/a

-US$95m

Dec 31 2021US$952kUS$580k

-US$84m

Sep 30 2021n/an/a

-US$80m

Jun 30 2021n/an/a

-US$82m

Mar 31 2021n/an/a

-US$73m

Dec 31 2020US$21mUS$168k

-US$66m

보상 대 시장: Andrew 의 총 보상 ($USD 3.79M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Andrew 의 보상이 증가했습니다.

CEO

Andrew Hirsch (53 yo)

3.8yrs

테뉴어

US$3,790,099

보상

Mr. Andrew J. Hirsch, M.B.A., is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer since October 2, 2020. Mr. Hirsch has been Director of C4 Therapeuti...

리더십 팀

이름위치테뉴어보상소유권
Andrew Hirsch
CEO, President & Director3.8yrsUS$3.79m0.31%
$ 973.6k
Kenneth Anderson
Co-Founderno dataUS$111.41k0.46%
$ 1.5m
Stewart Fisher
Chief Scientific Officer6.1yrsUS$1.53m0.34%
$ 1.1m
Leonard M. Reyno
Chief Medical Officerless than a yearUS$1.96m0.14%
$ 452.8k
Nathanael Gray
Co-Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Kendra Adams
CFO & Treasurerless than a year데이터 없음0.013%
$ 42.0k
Mark Mossler
Chief Accounting Officerless than a year데이터 없음0.0022%
$ 6.9k
Jolie Siegel
Chief Legal Officer & Corporate Secretary3.9yrsUS$3.38m0.014%
$ 46.0k
Kelly Schick
Chief People Officer3.4yrs데이터 없음0.014%
$ 46.0k
Isabel Chiu
Senior Vice President of Strategic Alliances & Business Development8.3yrs데이터 없음데이터 없음
Christopher Nasveschuk
Senior Vice President of Chemistry3.4yrs데이터 없음데이터 없음
Roy Pollock
Senior Vice President of Biological Sciences5.3yrs데이터 없음데이터 없음

3.6yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: CCCC 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Andrew Hirsch
CEO, President & Director3.7yrsUS$3.79m0.31%
$ 973.6k
Kenneth Anderson
Co-Founder8.5yrsUS$111.41k0.46%
$ 1.5m
Nathanael Gray
Co-Founder & Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Bruce Downey
Lead Independent Director8.5yrsUS$157.91k0.71%
$ 2.3m
Malcolm Salter
Independent Director8.5yrsUS$121.91k0.038%
$ 120.1k
Christopher Bowden
Member of Clinical Advisory Boardno data데이터 없음데이터 없음
Christopher Kirk
Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Ross Levine
Member of Scientific Advisory Board6.9yrs데이터 없음데이터 없음
Ronald H. Cooper
Independent Chairmanno data데이터 없음데이터 없음
Ryan Corcoran
Member of Scientific Advisory Board4.8yrs데이터 없음데이터 없음
Scott Armstrong
Member of Scientific Advisory Board6.9yrs데이터 없음데이터 없음
Utpal Koppikar
Independent Director2.3yrsUS$126.41k0.0082%
$ 26.2k

6.9yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: CCCC 의 이사회는 경험(평균 재직 기간 6.9 년)으로 간주됩니다.